MONROVIA, Calif.--(BUSINESS WIRE)--
Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced that company management will participate at two upcoming investor conferences:
-
Jefferies London Healthcare Conference
Date: Tuesday, November 15, 2022
Presentation Time: 8:00 a.m. GMT / 12:00 a.m. PST
Location: London
-
Piper Sandler 34th Annual Healthcare Conference
Date: Tuesday, November 29, 2022
Presentation Time: 12:30 p.m. EST / 9:30 a.m. PST
Location: New York
Live webcasts of these presentations will be available under "Events & Presentations" in the Investors section of the Company's website located at . Replays of the events will be available on the Xencor website for at least 30 days following the presentations.
About Xencor
Xencor is a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases. More than 20 candidates engineered with Xencor's XmAb® technology are in clinical development, and three XmAb medicines are marketed by partners. Xencor's XmAb engineering technology enables small changes to a protein's structure that result in new mechanisms of therapeutic action. For more information, please visit .
View source version on businesswire.com:
